Zacks Investment Research upgraded shares of Dermira (NASDAQ:DERM) from a sell rating to a hold rating in a research note released on Friday morning.
According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
Other research analysts have also issued research reports about the stock. Mizuho restated a buy rating on shares of Dermira in a research report on Friday, February 23rd. Cantor Fitzgerald set a $45.00 target price on shares of Dermira and gave the stock a buy rating in a research report on Monday, January 15th. Guggenheim lowered shares of Dermira from a buy rating to a neutral rating in a research report on Tuesday, March 6th. BidaskClub lowered shares of Dermira from a buy rating to a hold rating in a research report on Monday, February 5th. Finally, Leerink Swann increased their target price on shares of Dermira from $42.00 to $48.00 and gave the stock an outperform rating in a research report on Wednesday, January 17th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Dermira has an average rating of Buy and an average target price of $32.71.
Dermira stock opened at $9.10 on Friday. The firm has a market cap of $380.58, a PE ratio of -1.24 and a beta of 0.86. The company has a quick ratio of 5.28, a current ratio of 5.28 and a debt-to-equity ratio of 1.87. Dermira has a fifty-two week low of $8.55 and a fifty-two week high of $36.21.
Dermira (NASDAQ:DERM) last released its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.25) by ($0.09). The company had revenue of $1.34 million during the quarter, compared to the consensus estimate of $1.10 million. Dermira had a negative net margin of 6,678.29% and a negative return on equity of 62.07%. equities research analysts anticipate that Dermira will post -4.66 earnings per share for the current year.
In related news, SVP Christopher M. Griffith sold 18,458 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $27.05, for a total transaction of $499,288.90. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Eugene A. Bauer sold 3,000 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $28.55, for a total transaction of $85,650.00. Following the sale, the insider now owns 5,802 shares in the company, valued at approximately $165,647.10. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 26,758 shares of company stock worth $728,459. Company insiders own 13.30% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of DERM. Parametric Portfolio Associates LLC boosted its position in shares of Dermira by 56.2% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 31,918 shares of the biopharmaceutical company’s stock worth $930,000 after acquiring an additional 11,487 shares in the last quarter. New York State Common Retirement Fund boosted its position in shares of Dermira by 4.8% during the 3rd quarter. New York State Common Retirement Fund now owns 49,993 shares of the biopharmaceutical company’s stock worth $1,350,000 after acquiring an additional 2,308 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Dermira during the 3rd quarter worth approximately $474,000. Bank of New York Mellon Corp boosted its position in shares of Dermira by 6.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 191,220 shares of the biopharmaceutical company’s stock worth $5,163,000 after acquiring an additional 11,289 shares in the last quarter. Finally, Quantbot Technologies LP boosted its position in shares of Dermira by 75.4% during the 3rd quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock worth $145,000 after acquiring an additional 2,309 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.